Mitosis-targeted anti-cancer therapies: where they stand.
Mitosis-targeted anti-cancer therapies: where they stand.
复制标题
DOI：
10.1038/cddis.2012.148
复制
发表时间：
2012-10-18
影响因子：
9
通讯作者：
中科院分区：
文献类型：
--
作者：
临床上靶向癌细胞在有丝分裂期间处于最脆弱状态的策略已经引发了对有丝分裂细胞死亡（MCD）途径的大量研究。由于癌症的标志是细胞周期失调，因此抗有丝分裂疗法对转化细胞的异常增殖有效并不奇怪。此外，这些抗有丝分裂药物也具有高度选择性和敏感性。尽管有丝分裂选择性抑制剂的发现和开发速度很快，但人体对这些药物的反应的不可预测的复杂性仍然预示着临床成功的最大挑战。毫无疑问，需要弥合有前途的临床前试验和有效的转化床旁治疗之间的差距，促使进一步研究，以绘制MCD的机制途径，了解这些药物如何在体内发挥作用，以及更全面的靶点验证。在这篇综述中，目前的抗有丝分裂药物进行了总结，特别强调其临床疗效的评价以及其局限性。此外，我们还讨论了这些抑制剂在人体试验中缺乏活性的基础以及有丝分裂抗癌策略的潜在和未来方向。
The strategy of clinically targeting cancerous cells at their most vulnerable state during mitosis has instigated numerous studies into the mitotic cell death (MCD) pathway. As the hallmark of cancer revolves around cell-cycle deregulation, it is not surprising that antimitotic therapies are effective against the abnormal proliferation of transformed cells. Moreover, these antimitotic drugs are also highly selective and sensitive. Despite the robust rate of discovery and the development of mitosis-selective inhibitors, the unpredictable complexities of the human body's response to these drugs still herald the biggest challenge towards clinical success. Undoubtedly, the need to bridge the gap between promising preclinical trials and effective translational bedside treatment prompts further investigations towards mapping out the mechanistic pathways of MCD, understanding how these drugs work as medicine in the body and more comprehensive target validations. In this review, current antimitotic agents are summarized with particular emphasis on the evaluation of their clinical efficacy as well as their limitations. In addition, we discuss the basis behind the lack of activity of these inhibitors in human trials and the potential and future directions of mitotic anticancer strategies.
登录
查看更多内容
影响因子：
3.4
作者：
Burris, Howard A., III;Jones, Suzanne F.;LoRusso, Patricia
通讯作者：
LoRusso, Patricia
DOI：
10.1111/j.1582-4934.2001.tb00175.x
发表时间：
2001-10-01
影响因子：
5.3
作者：
Benga, G
通讯作者：
Benga, G
影响因子：
4.8
作者：
Dohi, T;Okada, K;Altieri, DC
通讯作者：
Altieri, DC
影响因子：
3.7
作者：
Cendan, JC;Souba, WW;Lind, DS
通讯作者：
Lind, DS
影响因子：
6.2
作者：
Croghan, Gary A.;Suman, Vera J.;Maples, William J.;Albertini, Mark;Linette, Gerald;Flaherty, Lawrence;Eckardt, John;Ma, Cynthia;Markovic, Svetomir N.;Erlichman, Charles
通讯作者：
Erlichman, Charles